Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Enteral immunomodulating nutrition modifies the gastrointestinal microbiota as well as improves the intestinal barrier integrity in patients with gastric and colorectal cancer in the perioperative period. As a consequence, it contributes to the reduction of the incidence of postoperative complications and diarrhea, which is a side effect of anti-cancer treatment often used preoperatively in this group of cancers.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| gastric cancer patients (immunonutrition) | Experimental | Experimental gastric cancer group will receive Impact Oral Nestlé Health Science/ Cubitan® Nutricia for 10 days. |
|
| gastric cancer patients (standard nutrition) | Active Comparator | These patients will receive Nutridrink® Nutricia/ Resource 2.0 Nestlé Health Science for 10 days. |
|
| colorectal cancer patients (immunonutrition) | Experimental | Experimental colorectal cancer group will receive Impact Oral Nestlé Health Science/ Cubitan® Nutricia for 10 days. |
|
| colorectal cancer patients (standard nutrition) | Active Comparator | These patients will receive Nutridrink® Nutricia/ Resource 2.0 Nestlé Health Science for 10 days. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Impact Oral Nestlé Health Science, Cubitan® Nutricia, Nutridrink® Nutricia, Resource 2.0 Nestlé Health Science | Dietary Supplement | Gastric and colorectal cancer patients will receive 1 bottle of immunonutrition or standard nutrition for 10 days. The aims of this study is to assess the effects of these immunonutrition on gut microbiota, intestinal permeability as well as inflammation of intestines in gastric and colorectal cancer patients. |
| Measure | Description | Time Frame |
|---|---|---|
| The impact of immunonutrition on gut microbiota in gastric and colorectal cancer patients. | The composition of gut microbiota (bacteria and fungi) will be assessed from stools. The amounts of bacteria/fungi will be presented using bioinformatics tools and there is no precisely described units (only the total number). | at baseline and after 7 and 10 days |
| Measure | Description | Time Frame |
|---|---|---|
| The impact of immunonutrition on intestinal permeability in gastric and colorectal cancer patients. | The ratio lactulose/mannitol will be described to assess intestinal permeability. There is no units. Only ratio of two numbers. | at baseline and after 7 and 10 days |
| The impact of immunonutrition on intestines in gastric and colorectal cancer patients. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
The calprotecin will be assessed. The unit is μg/g. |
| at baseline and after 7 and 10 days |
| ID | Term |
|---|---|
| D013274 | Stomach Neoplasms |
| D015179 | Colorectal Neoplasms |
| ID | Term |
|---|---|
| D005770 | Gastrointestinal Neoplasms |
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D004066 | Digestive System Diseases |
| D005767 | Gastrointestinal Diseases |
| D013272 | Stomach Diseases |
| D007414 | Intestinal Neoplasms |
| D003108 | Colonic Diseases |
| D007410 | Intestinal Diseases |
| D012002 | Rectal Diseases |
Not provided
Not provided